Search jobs 10-Apr-2021 Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting
Phase 1/1b results for the etrumadenant combination demonstrated a 4.2 month PFS, approximately double the 2 months reported for current standard of care therapies in the ≥3L mCRC setting
ARC-9, a randomized Phase 1b/2 platform study, has been initiated to further evaluate etrumadenant-zimberelimab combinations in the 2L, 3L and ≥3L+ mCRC settings
Our novel series of HIF-2α inhibitors, including AB521, a highly-potent molecule with a favorable pharmacokinetic profile, has been described for the first time; we remain on track to initiate clinical development for this program in 2H:21
The impact of chemotherapy on immune cells in the tumor microenvironment
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
E-Mail
PHILADELPHIA Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the
Abramson Cancer Center (ACC) at the University of Pennsylvania. Changing the microenvironment from so-called T cell poor to T cell rich with a CD40 agonist earlier could help slow eventual progression of the disease and prevent cancer from spreading in more patients.
The data which included 16 patients treated with the CD40 agonist selicrelumab was presented today by
Katelyn T. Byrne, PhD, an instructor of Medicine in the division of Hematology-Oncology in the Perelman School of Medicine at the University of Pennsylvania, during a plenary session at the American Association for Cancer Research annual meeting (Abstract #CT005).
Jubilant Therapeutics Presents Preclinical Data on its Brain Penetrant PRMT5 Inhibitor and Small Molecule PD-L1 Inhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2021
- JBI-1527, a potent, selective oral inhibitor of PD-L1 exhibited T-cell restoration and immune-mediated tumor growth suppression
- Data support the further development of PRMT5 inhibitor JBI-778 and PD-L1 inhibitor JBI-1527 for the treatment of unmet need in oncology
BEDMINSTER, N.J., April 10, 2021 /PRNewswire/ Jubilant Therapeutics Inc., a biopharmaceutical company advancing oral, small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that preclinical data from two programs evaluating the company s PRMT5 inhibitor and PD-L1 inhibitor as anti-cancer agents, will be presented today in a poster session at the American Association for Cancer Research (AACR) 2021 Annual Meeting taking place virtually from April 10-15, 2021.